8-K: SolenO Therapeutics Completes Merger with Neurocrine Biosciences

SolenO Therapeutics, Inc. has been acquired by Neurocrine Biosciences, Inc. through a tender offer and subsequent merger, with shareholders receiving $53.00 per share.

Summary

• SolenO Therapeutics, Inc. has been acquired by Neurocrine Biosciences, Inc. via a tender offer and merger.
• The tender offer, which commenced on April 20, 2026, successfully acquired approximately 88.9% of Soleno's outstanding shares.
• The merger was completed on May 18, 2026, making Soleno Therapeutics a wholly owned subsidiary of Neurocrine Biosciences.
• Shareholders who did not tender their shares will receive $53.00 per share in cash.
• Outstanding stock options and restricted stock units were cashed out at the offer price, with 'out of the money' options being cancelled.
• Company warrants were treated as cashless exercised.
• The Loan and Security Agreement dated December 17, 2024, and the 2014 Employee Stock Purchase Plan were terminated in connection with the merger.
• Soleno Therapeutics' common stock will be delisted from the Nasdaq Capital Market, and the company will seek to terminate its SEC reporting obligations.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive outcome for Soleno Therapeutics' shareholders who received a substantial cash premium, but neutral for the market as the company ceases to be a publicly traded entity.

Positives

• Shareholders received a premium of $53.00 per share in cash for their common stock.
• The tender offer was successful, with 88.9% of shares tendered, indicating strong shareholder acceptance of the acquisition terms.
• The merger was completed efficiently, with no further shareholder vote required due to the successful tender offer.
• All outstanding 'in the money' stock options and RSUs were converted into cash payments, providing value to option and RSU holders.

Negatives

• Shareholders who did not tender their shares will have them converted to the offer price, potentially missing out on any future upside if Soleno were to remain public.
• Holders of 'out of the money' stock options received no compensation.
• The company's common stock will be delisted from Nasdaq, reducing liquidity and public market visibility.
• The company will terminate its SEC reporting obligations, potentially reducing transparency for any residual stakeholders or the public.

Risks

• The delisting from Nasdaq and termination of reporting obligations could reduce future transparency.
• The cancellation of 'out of the money' stock options represents a loss of potential future value for those holders.

Future Outlook

With the completion of the merger, Soleno Therapeutics is now a wholly owned subsidiary of Neurocrine Biosciences. Its future operations and strategic direction will be integrated into Neurocrine's broader business. Public reporting obligations are expected to cease.

Management Comments

• The director resignations were tendered in connection with the Merger and were not a result of any disagreement between the Company and the directors on any matter relating to the Companys operations, policies or practices.
• The foregoing director and officer resignations were tendered in connection with the Merger and were not a result of any disagreement between the Company and such former directors and officers on any matter relating to the Companys operations, policies or practices.

Industry Context

StockSavvy.ai notes that this acquisition by Neurocrine Biosciences represents a typical consolidation trend within the biotechnology and pharmaceutical sectors, where larger companies acquire smaller, innovative firms to bolster their pipelines or gain access to specific technologies or therapeutic areas. The $53.00 per share offer price reflects a premium valuation, common in such strategic M&A activities.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received $53.00 per share in cash, realizing immediate value from their investment.
• Option Holders: Holders of 'in the money' options received cash payments; 'out of the money' options were cancelled with no compensation.
• Warrant Holders: Warrants were treated as cashless exercised.
• Employees: Potential impact on employment and compensation structures as the company is integrated into Neurocrine Biosciences; ESPP terminated.
• Creditors: Loan and Security Agreement terminated, indicating no outstanding debt under that agreement from Soleno Therapeutics.

Next Steps

• Delisting of Soleno Therapeutics' common stock from the Nasdaq Capital Market.
• Termination of Soleno Therapeutics' SEC reporting obligations.
• Integration of Soleno Therapeutics' operations into Neurocrine Biosciences.

Key Dates

Keywords

Merger, Acquisition, Tender Offer, Neurocrine Biosciences, Soleno Therapeutics, SEC Filing, Form 8-K, Delisting